Tag: Cancer: Lung
STS: Lung Cancer Screening Underused in the Community
All network providers were aware of the screening program; 15 percent never referred a patient
Many Advanced NSCLC Patients Not Getting Helpful Treatment
Study found 21 percent went without therapy, even though it could boost survival
Increasing Severity of Airflow Limitation Linked to Lung CA Risk
Linear relationship seen in population of older heavy cigarette smokers
Delayed Chemo After Surgery Still Beneficial in Lung Cancer
Patient recovery may mean longer time to chemotherapy, but treatment can still have benefit
2000 to 2011 Saw Shift in Treatment for Advanced NSCLC
Rise in use of pemetrexed, erlotinib, bevacizumab; longest treatment duration with these agents
Atezolizumab Effective in Late-Stage Non-Small-Cell Lung Cancer
Drug can extend survival by several months, with fewer adverse events
Stepped Care Likely to Be Cost-Effective in Head & Neck, Lung CA
Mean costs lower and mean number of quality-adjusted life-years higher in intervention group
Osimertinib Bests Platinum-Pemetrexed in T790M+ NSCLC
Significantly longer duration of progression-free survival with osimertinib vs platinum-pemetrexed
Intermittent Hypoxia Promotes Lung Tumor Cell Aggressiveness
IH-induced exosomes from mice significantly promote TC1 malignant properties
Updated Index Predicts Survival in NSCLC With Brain Metastases
Significant prognostic factors include four factors from earlier index, plus EGFR and ALK alterations
